This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
AMAG Pharmaceuticals, Inc.
Drug Names(s): coca iron oxide, ferumoxytol, Rienso (EU)
Description: Ferumoxytol is an intravenous iron replacement therapy for the treatment of anemia in chronic kidney disease (CKD) patients. It is a semi-synthetic carbohydrate-coated iron oxide. The drug is given as an intravenous injection (IV push).
AMAG and 3SBio
In May 2008, AMAG Pharmaceuticals and 3SBio announced the signing of a development and commercialization agreement for ferumoxytol. Under the terms of the agreement, AMAG grants 3SBio exclusive rights to develop and commercialize ferumoxytol in China.
In January 2014, AMAG reported that they mutually terminated the agreement with 3SBio as regulatory approval in China could not be obtained within the agreed upon time period.
AMAG and Takeda
In April 2010, AMAG and Takeda entered into a license, development and commercialization agreement related to Feraheme (ferumoxytol) Injection for intravenous (IV) use in all therapeutic indications. Takeda receives an exclusive license to Feraheme for all therapeutic applications in 5 regions, including Europe, Canada, Turkey, the Commonwealth of Independent States and Asia Pacific countries, excluding Japan, China and Taiwan. AMAG receives a $60 million upfront payment and is eligible to receive...See full deal structure in Biomedtracker
Additional information available to subscribers only: